Vol 54, No 3 (2020)
Response to Letter to the Editors
Published online: 2020-06-25
Response to “Does amantadine have a protective effect against COVID-19?”
1
, 1
, 1
Abstract
Not available
Keywords: COVID-19amantadinememantineParkinson’s disease
References
- Lippi A, Domingues R, Setz C, et al. SARS-CoV-2: At the Crossroad Between Aging and Neurodegeneration. Mov Disord. 2020; 35(5): 716–720.
- Richardson S, Hirsch JS, Narasimhan M, et al. and the Northwell COVID-19 Research Consortium. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 [Epub ahead of print].
- Reeve A, Simcox E, Turnbull D. Ageing and Parkinson's disease: why is advancing age the biggest risk factor? Ageing Res Rev. 2014; 14: 19–30.
- Tipton PW, Wszolek ZK. What can Parkinson's disease teach us about COVID-19? Neurol Neurochir Pol. 2020; 54(2): 204–206.
- Brison E, Jacomy H, Desforges M, et al. Novel treatment with neuroprotective and antiviral properties against a neuroinvasive human respiratory virus. J Virol. 2014; 88(3): 1548–1563.
- Cortés Borra A. Does amantadine have a protective effect against COVID-19? Neurol Neurochir Pol. 2020 [Epub ahead of print].
- Fasano A, Cereda E, Barichella M, et al. COVID-19 in Parkinson's Disease Patients Living in Lombardy, Italy. Mov Disord. 2020 [Epub ahead of print].
- Rejdak K, Grieb P. Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment. Mult Scler Relat Disord. 2020 [Epub ahead of print]; 42: 102163.
- Arons MM, Hatfield KM, Reddy SC, et al. Public Health–Seattle and King County and CDC COVID-19 Investigation Team. Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility. N Engl J Med. 2020; 382(22): 2081–2090.
